Metabolomics Market Revenue to Attain USD 12.59 Bn by 2033

11 Sep 2025

Share :

Table of Content

1. Metabolomics Market Revenue and Trends 2025 to 2033 2. What are the Key Factors Influencing the Growth of the Metabolomics Market? 3. Segment Insights 4. Regional Insights 5. Metabolomics Market Coverage 6. Metabolomics Market Key Players

Metabolomics Market Revenue and Trends 2025 to 2033

The global metabolomics market revenue reached USD 4.31 billion in 2025 and is predicted to attain around USD 12.59 billion by 2033 with a CAGR of 14.34%. The growth of the market is attributed to the increasing demand for personalized medicine, biomarkers, and high-throughput screening.

What are the Key Factors Influencing the Growth of the Metabolomics Market?

There are several factors influencing the growth of the market for metabolomics. Firstly, the global trend toward precision medicine has increased the use of metabolomic profiling. Secondly, the growing importance of biomarker discoveries for early disease diagnosis, particularly in cancer, neurodegenerative diseases, and metabolic syndromes, drives companies to use metabolomic technologies. Moreover, advancements in analytical instrumentation, especially coupling mass spectrometry with ultra-performance chromatography (UPLC), have improved sensitivity, throughput, and accuracy in metabolite analysis. 
New partnerships are emerging between pharmaceutical companies, government entities, and academic institutions to develop research infrastructure and integrate metabolomics into drug development, creating immense opportunities in the market. Government funding for metabolomics research also opens up new growth prospects.

Segment Insights

• By product & service, the instruments (mass spectrometry) segment held the largest share of the market in 2024 due to its critical role in metabolomic profiling. It is the gold standard for metabolite identification and quantification, making it indispensable in both research and clinical applications.
• By application, the biomarker discovery segment led the market in 2024 due to the increased focus of clinicians and researchers on detecting specific metabolic signatures related to disease. The growing demand for early disease detection, personalized medicine, and targeted therapies also bolsters the segment.
• By study type, the targeted metabolomics is the dominant segment due to its high specificity, accuracy, and reproducibility in analyzing known metabolites.
• By indication, the oncology segment captured the largest share of the metabolomics market in 2024. This is mainly due to the growing use of metabolomics in cancer research for early detection, diagnosis, and personalized treatment strategies.
• By end user, the pharmaceutical & biotechnology companies segment contributed the largest market share in 2024, as they heavily rely on metabolomic data for drug discovery and development.

Regional Insights

North America maintained dominance in the metabolomics market by holding a major share in 2024. This is mainly due to its robust research infrastructure and advanced healthcare system. The region also benefits from the presence of leading pharmaceutical and biotechnology companies that are focusing on developing novel drugs. Increased healthcare funding and substantial R&D investments also bolstered the regional market growth.

Meanwhile, Asia Pacific is expected to experience rapid growth in the upcoming period, driven by government initiatives to advance precision healthcare, high spending on biotechnology, and growing demand for sophisticated diagnostic solutions. Rising healthcare expenditure and growing demand for precision medicine also contribute to regional market growth.

Metabolomics Market Coverage

Recent Developments

• In June 2025, Thermo Fisher Scientific has launched the Orbitrap™ Astral™ Zoom and Orbitrap™ Excedion™ Pro mass spectrometers, offering exceptional analytical performance and speed. The new Orbitrap systems strengthen Thermo Fisher’s proteomics and biopharma portfolio, supporting deeper scientific discovery. (Source: https://ir.thermofisher.com)
• In June 2024, Bruker Corporation launched the timsTOF Ultra 2 system, offering enhanced sensitivity for deep profiling of small cells and subcellular organelles, along with greater sample loading flexibility. (Source: https://www.bruker.com)

Metabolomics Market Key Players

• Agilent Technologies, Inc.  
• Thermo Fisher Scientific Inc.  
• Bruker Corporation  
• Waters Corporation  
• Shimadzu Corporation  
• Danaher Corporation (Sciex)  
• PerkinElmer, Inc.  
• Bio-Rad Laboratories, Inc.  
• Metabolon, Inc.  
• Human Metabolome Technologies, Inc.  
• LECO Corporation  
• Creative Proteomics  
• Chenomx Inc.  
• Biocrates Life Sciences AG  
• Owlstone Medical Ltd.  
• MetaboAnalyst (University of Alberta spin-off)  
• Evotec SE  
• Seoul National University R&DB Foundation 

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6741

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344